International Journal of Radiation Research
نشریه پرتو پژوه
Int J Radiat Res
Basic Sciences
http://ijrr.com
79
journal79
2322-3243
2345-4229
10.61186/ijrr
en
jalali
1401
1
1
gregorian
2022
4
1
20
2
online
1
fulltext
en
Combination of ultrasound with BRAF V600E gene detection for the evaluation of aggressive behavior of papillary thyroid microcarcinoma
Radiation Biology
Radiation Biology
تحقيق بديع
Original Research
<div style="text-align: justify;"><span style="font-size:10pt"><span style="text-justify:newspaper"><span style="text-kashida-space:50%"><span style="line-height:119%"><span style="font-family:Calibri"><span style="color:black"><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Background</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">The Japanese clinical guidelines and the 2015 American Thyroid Association Management Guidelines recommend that </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">indolent </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-US">papillary thyroid microcarcinoma</span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-US"> (PTMC) </span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">be monitored actively and that patients with aggressive PTMC immediately undergo surgery. This study aimed to establish a stage model and provide a reference for the preoperative identification of aggressive PTMC and indolent PTMC, which might guide the treatment of PTMC. </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Materials and Methods</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">Risk factors for the aggressive PTMC were identified through multivariate logistic regression analysis. According to the regression coefficient, each risk factor was assigned a risk score; thereafter, a </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-US">risk score (RS)</span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US"> model and a stage model were established.</span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Results</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">The </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">tumor’s </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">largest</span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">diameter > 6 mm, </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-US">BRAFV600E (v-Raf murine sarcoma viral oncogene homolog B1, V600E) </span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">mutation, ultrasound-suspected lymph node metastasis, ultrasound-suspected extrathyroidal extension, and microcalcification were identified as risk factors for aggressive PTMC. The stage model was divided into three stages: stage I (RS=0.0; predictive probability for PTMC aggressiveness <10%), stage II (RS=1.0–2.3; predictive probability for PTMC aggressiveness, 10–50%), stage III (RS=3.2–7.6; predictive probability for PTMC aggressiveness, >50%). Based on the abovementioned results, stages I and II were considered to be probably indolent PTMC, and stage III was considered as probably aggressive PTMC. </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Conclusion</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">We suggest that patients with stages I and II PTMC be recommended for active surveillance, while those with stage III PTMC be recommended for immediate surgery.</span></span></span></span></span></span></span></span></span></div>
Papillary thyroid microcarcinoma, ultrasound, BRAFV600E, aggressive.
389
395
http://ijrr.com/browse.php?a_code=A-10-1-921&slc_lang=en&sid=1
W.
Liu
7900319475328460021802
7900319475328460021802
No
Department of Ultrasound, the Second Hospital of Anhui Medical University, 230601, HeFei, AnHui, China
M.
Peng
714200630@qq.com
7900319475328460021803
7900319475328460021803
Yes
Department of Ultrasound, the Second Hospital of Anhui Medical University, 230601, HeFei, AnHui, China
F.
Jiang
7900319475328460021804
7900319475328460021804
No
Department of Ultrasound, the Second Hospital of Anhui Medical University, 230601, HeFei, AnHui, China
S.Y.
Wang
7900319475328460021805
7900319475328460021805
No
Department of Head and Neck, the First Affiliated Hospital of USTC West District, 230000, HeFei, AnHui, China
J.J.
Liu
7900319475328460021806
7900319475328460021806
No
Department of Head and Neck, the First Affiliated Hospital of USTC West District, 230000, HeFei, AnHui, China
K.
Tao
7900319475328460021807
7900319475328460021807
No
Department of Head and Neck, the First Affiliated Hospital of USTC West District, 230000, HeFei, AnHui, China
J.
He
7900319475328460021808
7900319475328460021808
No
Department of Head and Neck, the First Affiliated Hospital of USTC West District, 230000, HeFei, AnHui, China